Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1987 1
1988 1
1990 1
1991 1
1992 1
1993 3
1994 2
1997 2
1998 8
1999 7
2000 8
2001 5
2002 5
2003 7
2004 2
2005 1
2006 4
2007 4
2008 5
2009 5
2010 3
2011 1
2012 3
2013 7
2014 5
2015 4
2016 3
2017 2
2018 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Results by year
Filters applied: . Clear all
Page 1
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Ishida T, et al. Among authors: akinaga s. Br J Haematol. 2015 Jun;169(5):672-82. doi: 10.1111/bjh.13338. Epub 2015 Mar 2. Br J Haematol. 2015. PMID: 25733162 Free PMC article. Clinical Trial.
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Ishida T, et al. Among authors: akinaga s. J Clin Oncol. 2012 Mar 10;30(8):837-42. doi: 10.1200/JCO.2011.37.3472. Epub 2012 Feb 6. J Clin Oncol. 2012. PMID: 22312108 Clinical Trial.
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Ogura M, et al. Among authors: akinaga s. J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10. J Clin Oncol. 2014. PMID: 24616310 Clinical Trial.
Development of radicicol analogues.
Soga S, Shiotsu Y, Akinaga S, Sharma SV. Soga S, et al. Among authors: akinaga s. Curr Cancer Drug Targets. 2003 Oct;3(5):359-69. doi: 10.2174/1568009033481859. Curr Cancer Drug Targets. 2003. PMID: 14529387 Review.
Porous Peptide Complexes by a Folding-and-Assembly Strategy.
Sawada T, Yamagami M, Akinaga S, Miyaji T, Fujita M. Sawada T, et al. Among authors: akinaga s. Chem Asian J. 2017 Jul 18;12(14):1715-1718. doi: 10.1002/asia.201700458. Epub 2017 Jun 6. Chem Asian J. 2017. PMID: 28380285
Engineered therapeutic antibodies with improved effector functions.
Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Kubota T, et al. Among authors: akinaga s. Cancer Sci. 2009 Sep;100(9):1566-72. doi: 10.1111/j.1349-7006.2009.01222.x. Epub 2009 May 18. Cancer Sci. 2009. PMID: 19538497 Free article. Review.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page